Suven Life Sciences Share Price Today | Stock Price & Suven Life Sciences Share Screener
As of October 5, 2026, the live Suven Life Sciences share price (NSE: SUVEN) is ₹306.30 on NSE and ₹306.10 on BSE, down 0.65% from the previous close, with shares trading between ₹305.20 and ₹316.00 in today's trading session, and a 52-week range of ₹126.65–₹392.05. Check Suven Life Sciences yearly highs lows for the annual price range and momentum. Use the Suven Life Sciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Suven Life Sciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹11 and net income of ₹-128, with EBITDA of ₹-125, an operating margin of -3711.0% and a profit margin of -1163.6%.
Suven Life Sciences Share Price Chart
Track the current stock price of Suven Life Sciences with an interactive chart. Analyse SUVEN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Suven Life Sciences stock quote in one place.
The quote of ₹306.30 sits between the 52-week low of ₹126.65 and the 52-week high of ₹392.05, and the latest session moved -0.65% from the previous close.
Suven Life Sciences Company Profile - Fundamental Screener
Screen Suven Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUVEN shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Technology industry, and it trades under ISIN INE495B01038.
Company Details
Classification
Identifiers and Leadership
Suven Life Sciences Balance Sheet Screener
Screen SUVEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹624, up from ₹135 in 2025.
Latest statistics put total assets at ₹624 and shareholder funds at ₹591, with a leverage ratio of 0.02.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 624 | 135 | 285 | 389 | 108 | 128 | 182 | 303 | 919 | 816 |
| Current Assets | 547 | 76 | 257 | 252 | 67 | 103 | 66 | 281 | 570 | 492 |
| Fixed Assets | 73 | 60 | 28 | 37 | 38 | 21 | 25 | 22 | 308 | 306 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 14 | 2 | 1 | 3 | 4 | 5 | 12 | 25 | 30 | 30 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 591 | 110 | 270 | 375 | 96 | 108 | 143 | 239 | 767 | 667 |
| Share Capital | 26 | 22 | 22 | 22 | 15 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 410 | 88 | 248 | 354 | 82 | 58 | 131 | 226 | 755 | 654 |
Suven Life Sciences Income Statement Screener - Profit & Revenue Analysis
Screen Suven Life Sciences income statement and profit fundamentals. Analyze SUVEN quarterly results. Suven Life Sciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹11 and net profit was ₹-128, equal to earnings per unit of ₹-4.84, at an operating margin of -3711%.
In that period expenses were ₹136, interest cost ₹1 and tax ₹0. The next period listed, 2026-Mar, shows revenue of ₹8 and net profit of ₹-46.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 11 | 8 | 6 | 5 | 3 | 3 | 3 | 7 | 5 | 7 | 9 | 16 | 9 | 8 | 5 |
| Expenses | 136 | 52 | 106 | 81 | 53 | 45 | 41 | 55 | 32 | 33 | 49 | 27 | 32 | 34 | 55 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | -125 | -44 | -101 | -76 | -50 | -43 | -38 | -48 | -27 | -26 | -40 | -11 | -22 | -26 | -49 |
| Operating Profit % | -3711.00% | -3331.00% | -3678.00% | -8671.00% | -2714.00% | -2981.00% | -2435.00% | -2032.00% | -3023.00% | -1267.00% | -1885.00% | -768.00% | -737.00% | -1208.00% | -1720.00% |
| Depreciation | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | -128 | -46 | -102 | -77 | -52 | -44 | -39 | -50 | -28 | -28 | -42 | -13 | -24 | -28 | -51 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -128 | -46 | -102 | -77 | -52 | -44 | -39 | -50 | -28 | -27 | -42 | -13 | -24 | -28 | -51 |
| EPS | -4.84 | -2.02 | -4.55 | -3.48 | -2.36 | -2.02 | -1.79 | -2.27 | -1.29 | -1.22 | -1.92 | -0.58 | -1.10 | -1.17 | -2.90 |
Suven Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen SUVEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹300, and net cash flow was an outflow of ₹5.
Over the same period, investing activities used ₹462 and financing activities provided ₹757.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -300 | -155 | -116 | -116 | -128 | -96 | -135 | -53 | 70 | 109 |
| Investing Activities | -462 | 155 | 94 | -248 | -22 | 56 | 146 | 30 | -1 | -311 |
Financing and Net Cash | ||||||||||
| Financing Activities | 757 | -1 | -1 | 396 | 146 | 35 | 3 | 5 | -52 | -30 |
| Net Cash Flow | -5 | -1 | -22 | 32 | -4 | -5 | 14 | -18 | 17 | -232 |
Suven Life Sciences Shareholding Pattern Screener
See Suven Life Sciences shareholding pattern with promoter, FII, and DII holdings. Check Suven Life Sciences promoter holding and ownership changes for SUVEN on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Aug, promoters held 65.47%, foreign institutions 0.48%, domestic institutions 2.73% and the public 24.40%, spread across 66,647 shareholders.
The shareholder count was 66,647 in 2026-Aug, compared with 66,647 in 2026-Jul.
| Item | 2026-Aug | 2026-Jul | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jul | 2025-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 65.47% | 65.47% | 70.08% | 70.15% | 67.36% | 67.36% | 67.43% | 70.27% |
Institutional Investors | ||||||||
| FII Holding | 0.48% | 0.48% | 0.57% | 0.91% | 1.07% | 1.18% | 0.56% | 0.59% |
| DII Holding | 2.73% | 2.73% | 2.93% | 4.62% | 3.39% | 3.39% | 3.41% | 0.02% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 24.40% | 24.40% | 21.37% | 19.45% | 22.29% | 22.25% | 22.24% | 23.17% |
| Other Holding | 6.92% | 6.92% | 5.06% | 4.87% | 5.90% | 5.82% | 6.37% | 5.95% |
| Shareholder Count | 66,647 | 66,647 | 66,791 | 64,037 | 64,381 | 64,921 | 65,574 | 66,159 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Suven Life Sciences. Suven Life Sciences dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.50 | 7.61% |
| 2018-March | ₹1.50 | 0.57% |
| 2017-March | ₹1.00 | 12.85% |
Suven Life Sciences Stock Index Membership - Nifty & Sensex
See which indices include Suven Life Sciences stock. Check SUVEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 3 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
Suven Life Sciences Market Events Screener - Corporate Actions
Get Suven Life Sciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Suven Life Sciences stock events that may affect SUVEN share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Annual General Meeting dated August 25, 2026, with a record date of August 25, 2026.
It is followed by Quarterly Result Announcement dated August 6, 2026 and Quarterly Result Announcement dated May 13, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-25 | 2026-08-25 | Annual General Meeting | NA | 71.99% |
| 2026-08-06 | 2026-08-06 | Quarterly Result Announcement | NA | 4.64% |
| 2026-05-13 | 2026-05-13 | Quarterly Result Announcement | NA | 4.67% |
| 2026-01-29 | 2026-01-29 | Quarterly Result Announcement | NA | -2.40% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -5.22% |
| 2025-08-22 | 2025-08-22 | Annual General Meeting | NA | 53.37% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -13.24% |
| 2025-06-05 | 2025-06-05 | Extraordinary General Meeting | NA | 53.37% |
| 2025-05-13 | 2025-05-13 | Quarterly Result Announcement | NA | 16.60% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -8.29% |
| 2024-10-29 | 2024-10-29 | Quarterly Result Announcement | NA | -7.61% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 26.09% |
| 2022-10-17 | 2022-10-18 | Rights | 1:2 | 4.83% |
Suven Life Sciences Competitors Screener - Peer Stocks Comparison
Screen SUVEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 9 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Syngene International | 14,472 | 65.99 | 3,809 | 2.56% | 317 | 31.20 |
| Indegene | 14,368 | 35.70 | 3,583 | 21.58% | 401 | 53.26 |
| Suven Life Sciences | 8,699 | -24.74 | 21 | 19.32% | -276 | 34.07 |
| Vimta Labs | 2,602 | 35.09 | 322 | 0.22% | 41 | 39.40 |
| Bilcare | 231 | -35.68 | 764 | -5.33% | -17 | 51.60 |
| TAKE | 180 | 14.49 | 61 | 497.06% | 4 | 27.68 |
| Jeevan Scientific Technology | 172 | 33.22 | 62 | 29.56% | 2 | 62.97 |
| Adeshwar Meditex | 24 | 33.09 | 56 | -33.10% | 1 | 53.57 |
| Vanta Bioscience | 15 | 143.27 | 2 | -13.33% | 0 | 48.79 |
Suven Life Sciences Company Announcements - News & Reports Screener
Screen SUVEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 30, 2026.
The next most recent announcements are dated September 3, 2026 and August 25, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-08-25 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-25 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-08-07 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-06 | Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-06 | Un-Audited Financial Results For The Quarter Ended 30Th June 2026 | - |
| 2026-07-31 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-30 | Board Meeting Intimation for Consideration Of Un-Audited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2026 | - |
| 2026-07-30 | Letter To Shareholders Regarding Annual Report FY 2025-26 | - |
| 2026-07-30 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-30 | Notice Of 37Th Annual General Meeting (AGM) Of The Company | - |
| 2026-07-30 | Reg. 34 (1) Annual Report. | - |
| 2026-07-20 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-07-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-07-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-07-08 | Revised Outcome Of The Meeting Of Board Of Directors- Incorporation Of Wholly Owned Subsidiary (WOS) In Singapore | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹306.30, within a 52-week range of ₹126.65 to ₹392.05. The P/E ratio is -24.74 and the P/B ratio is 12.73, with earnings per unit of ₹-12.13. Market capitalisation stands at ₹8,698.69 Cr. The company operates in the Healthcare sector, in the Healthcare Technology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.